Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Operations: 2023-2025

Historic Cash from Operations for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to -$28.8 million.

  • Tonix Pharmaceuticals Holding's Cash from Operations fell 53.09% to -$28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.8 million, marking a year-over-year decrease of 9.02%. This contributed to the annual value of -$60.9 million for FY2024, which is 40.27% up from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Cash from Operations is -$28.8 million, which was down 94.04% from -$14.8 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Cash from Operations' 5-year high stood at -$9.9 million during Q2 2024, with a 5-year trough of -$32.9 million in Q1 2023.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Cash from Operations averaged around -$20.3 million, with its median value being -$18.8 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 57.55% in 2024, then tumbled by 53.09% in 2025.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Cash from Operations stood at -$22.3 million in 2023, then surged by 34.51% to -$14.6 million in 2024, then tumbled by 53.09% to -$28.8 million in 2025.
  • Its Cash from Operations stands at -$28.8 million for Q3 2025, versus -$14.8 million for Q2 2025 and -$16.6 million for Q1 2025.